Text Size
43 studies found for:    autoinflammatory

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
autoinflammatory (43 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results 		Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes:;   Familial Cold Autoinflammatory Syndrome;   Muckle Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: Canakinumab (ACZ885)
2 Withdrawn A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Conditions: Muckle Wells Syndrome;   Autoinflammatory;   Behcet's Disease
Intervention: Drug: XOMA 052
3 Completed Internleukin-1 Trap to Treat Autoinflammatory Disease
Conditions: Inflammation;   Familial Mediterranean Fever;   Still's Disease, Adult-Onset
Intervention: Drug: IL-1 Trap
4 Recruiting Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
5 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: canakinumab
6 Unknown † The Efficacy and Safety of ITF2357 in AIS
Conditions: Autoinflammatory Syndromes;   HIDS;   TRAPS;   Schnitzler's Syndrome
Intervention: Drug: ITF2357
7 Recruiting Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
8 Recruiting Studies of the Natural History and Pathogenesis and Outcome of Neonatal Onset Multisystem Inflammatory Disease (NOMID/CAPS, DIRA, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
9 Completed
Has Results 		Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo
10 Available Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Condition: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
Intervention: Drug: Baricitinib
11 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
12 Completed
Has Results 		Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
Condition: Muckle Wells Syndrome
Interventions: Drug: ACZ885;   Drug: Placebo
13 Completed Ilaris (Canakinumab) in the Schnitzler Syndrome
Condition: Schnitzler Syndrome
Intervention: Drug: Ilaris
14 Recruiting Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
Condition: Schnitzler Syndrome
Intervention:
15 Completed
Has Results 		Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Condition: Familial Mediterranean Fever
Interventions: Drug: Rilonacept;   Drug: Placebo
16 Recruiting Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
17 Recruiting Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Condition: Periodic Disease
Intervention:
18 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Conditions: MUD Transplant;   AlloPBSC;   Congenital Immunodeficiencies;   HLA Matched Transplant;   BMT
Interventions: Drug: Busulfan;   Drug: Campath-1 H;   Drug: Sirolimus;   Procedure: BMT;   Procedure: Apheresis;   Procedure: Total Body Irradiation;   Procedure: GCSF Injections
19 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
20 Recruiting Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years